Gelteq (GELS) Equity Ratio (2023 - 2025)

Gelteq (GELS) recorded quarterly Equity Ratio of 0.74 in Q2 2025, up 1.09% quarter-over-quarter from 0.73 in Q2 2024, and up 1.09% on a YoY basis from 0.73 in Q2 2024.

Gelteq (GELS) Equity Ratio (2023 - 2025) Analysis & Trends

Gelteq's Equity Ratio history runs 3 years deep, the most recent figure standing at 0.74 for Q2 2025.

  • In Q2 2025, Equity Ratio rose 1.09% year-over-year to 0.74; the TTM figure through Jun 2025 stood at 0.74 (up 1.09% YoY), while the FY2025 annual figure was 0.74, up 1.09% from the prior year.
  • Equity Ratio was 0.74 for Q2 2025 at Gelteq, up from 0.73 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.83 in Q2 2023 to a low of 0.73 in Q2 2024.
  • Historically, Equity Ratio has averaged 0.76 across 3 years, with a median of 0.74 in 2025.
  • The sharpest annual moves came in 2024 and 2025: Equity Ratio dropped 12.23% in 2024, then advanced 1.09% in 2025.
  • A 3-year view of Equity Ratio shows it stood at 0.83 in 2023, then decreased by 12.23% to 0.73 in 2024, then advanced by 1.09% to 0.74 in 2025.
  • The last three Equity Ratio figures came in at 0.74 (Q2 2025), 0.73 (Q2 2024), and 0.83 (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Ratio (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 0.21
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 0.21
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 0.88
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn 0.73
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 0.69
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 0.49
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 0.41
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn 0.20
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 0.52
10 Gelteq 10.57 Mn 10.34 Mn - 0.74

Historic Data

Download Data
DateValue
Jun 30, 2025 0.74
Jun 30, 2024 0.73
Jun 30, 2023 0.83